AbbVie acquired Capstan Therapeutics, Inc. for $1.9 billion upfront, a transaction announced in June 2025, structured as all cash (asset acquisition).
Capstan Therapeutics, Inc. operates in In vivo cell engineering / immunology, is based in San Diego, California. Capstan is a clinical-stage biotech advancing in vivo engineering of cells through RNA delivery using targeted lipid nanoparticles (tLNPs). The transaction includes CPTX2309, an in vivo CD19 CAR-T candidate. The FY2025 10-K records approximately $1.9 billion of upfront charges related to the acquisition.
Adds an in vivo cell-engineering platform and a potential first-in-class in vivo CAR-T candidate to AbbVie's immunology pipeline.
Advisory firms were not disclosed for this transaction.